Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Serious adverse events · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.74 [0.48, 1.15]
2 studies · 541 participants
Moderate

Serious adverse events · induction of remission in Crohn's disease

Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease 2016 · Cochrane Headline outcomes only
RR 0.83 [0.58, 1.2]
4 studies · 2023 participants
Moderate